Revised forecast
Fiscal year ending March 2027 · Six months and full yearPrevious forecast published 13 May 2026 (full year), 31 July 2026 (interim period)The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Because sales, led by Gemtesa in the United States, remained strong, the yen was weaker than assumed, and higher revenue is expected to increase gross profit, while sales-related expenses are also expected to rise to support sales expansion.
| Item | Details |
|---|---|
| Net Sales | ¥540,000 million → ¥565,000 million（+4.6%） |
| Operating profit | ¥90,000 million → ¥104,000 million（+15.6%） |
| Profit attributable to owners of the parent | ¥77,000 million → ¥94,000 million（+22.1%） |
| Net income per share | 172.89 Yen/sen → 211.07 Yen/sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Six months and full year |
| Publication date of previous forecast | 13 May 2026 (full year), 31 July 2026 (interim period) |
| Previous-period results | Fiscal year ended March 2026: revenue ¥453,294 million, operating profit ¥105,908 million, profit attributable to owners of the parent ¥106,865 million, basic earnings per share ¥268.99 |
| Reason for the revision | Because sales, led by Gemtesa in the United States, remained strong, the yen was weaker than assumed, and higher revenue is expected to increase gross profit, while sales-related expenses are also expected to rise to support sales expansion. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The interim upside was driven by strong sales of overactive bladder treatment Gemtesa and other products in the United States, a weaker yen than assumed, and selling, general and administrative expenses and research and development expenses coming in slightly below expectations excluding foreign exchange effects. For the full year, the company expects US sales to exceed plan and revenue to increase following a change in its exchange rate assumptions, as well as higher gross profit resulting from increased revenue, while also anticipating higher sales-related expenses to support sales expansion.